type (Del19 or L858R) and brain metastases (presence/absence). There were 3 co-primary endpoints: progression free survival (PFS) by independent review, time to treatment failure (TTF) and overall survival (OS). Secondary endpoints included objective response rate (ORR), disease control rate, tumour shrinkage and safety. Results: Pts received daily afatinib (40 mg; n = 160) or gefitinib (250 mg; n = 159) until radiological disease progression or beyond if deemed beneficial by investigator. Baseline characteristics were balanced in treatment arms (Asian: 58.8% vs 55.3%, EGFR Del19: 57.5% vs 58.5%), respectively, with slightly more females in the gefitinib arm (56.9% vs 66.7%). PFS was significantly improved with afatinib vs gefitinib (HR = 0.73; 95% CI, 0.57-0.95; p = 0.017), as was TTF (HR = 0.73; 95% CI, 0.58-0.92; p = 0.007). Consistent treatment benefit was seen across the subgroups including mutation type and race. Independently assessed ORR was significantly higher with afatinib vs gefitinib (70% vs 56%, p = 0.008). OS data are not mature. Common grade 3 related adverse events (AEs) were: diarrhoea (12.5%) and rash/acne (9.4%) with afatinib, and alanine aminotransferase increase (8.2%) with gefitinib. There was no drug-related interstitial lung disease for afatinib (vs 4 gefitinib pts; 2.5%). Discontinuation due to drug-related AEs was the same in each arm (6.3%). Conclusions: Afatinib significantly improved PFS compared with gefitinib as first-line treatment of EGFR m+ pts. Afatinib treatment benefit was also seen for TTF and ORR. The AE profiles for both drugs were manageable and discontinuation due to AEs was equally low.

